Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis.
about
Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetesDipeptidyl Peptidase 4 Inhibitors and the Risk of Cardiovascular Disease in Patients with Type 2 Diabetes: A Tale of Three StudiesA systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetesUsing real-world data to evaluate the association of incretin-based therapies with risk of acute pancreatitis: a meta-analysis of 1,324,515 patients from observational studies.Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trialGenetic ablation or pharmacological blockade of dipeptidyl peptidase IV does not impact T cell-dependent immune responses.Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis.Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes.GLP-1(28-36)amide, the Glucagon-like peptide-1 metabolite: friend, foe, or pharmacological folly?The evolving place of incretin-based therapies in type 2 diabetesBiocatalytic asymmetric synthesis of chiral amines from ketones applied to sitagliptin manufacture.Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus.Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies.Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapiesEffect of the addition of sitagliptin and miglitol on insulin-treated type 2 diabetes.The effect of sitagliptin on cardiovascular risk profile in Korean patients with type 2 diabetes mellitus: a retrospective cohort studyEffects of sitagliptin beyond glycemic control: focus on quality of life.Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema.Treating type 2 diabetes: incretin mimetics and enhancers.Defining the importance of daily glycemic control and implications for type 2 diabetes management.Incretin-based therapies: viewpoints on the way to consensus.DPP-4 inhibitors in clinical practice.Consensus Statement on Dose Modifications of Antidiabetic Agents in Patients with Hepatic Impairment.Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin.DPP-4 inhibitors: impact on glycemic control and cardiovascular risk factors.Current treatment options for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.Antihyperglycaemic therapies and cancer risk.Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes.Diabetes therapies in hemodialysis patients: Dipeptidase-4 inhibitors.Impact of clinical evidence communications and drug regulation changes concerning rosiglitazone on prescribing patterns of antidiabetic therapies.Interpreting Cardiovascular Endpoints in Trials of Antihyperglycemic Drugs.Acute pancreatitis in patients with type 2 diabetes mellitus treated with dipeptidyl peptidase-4 inhibitors: a population-based nested case-control study.Drug-induced generalized skin eruption in a diabetes mellitus patient receiving a dipeptidyl peptidase-4 inhibitor plus metformin.Safety and tolerability of sitagliptin in type 2 diabetes: pooled analysis of 25 clinical studies.Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors.Practical, asymmetric route to sitagliptin and derivatives: development and origin of diastereoselectivity.GLP-1-based therapy for diabetes: what you do not know can hurt you.Sitagliptin manufacture: a compelling tale of green chemistry, process intensification, and industrial asymmetric catalysis.Anti-inflammatory effects of linagliptin in hemodialysis patients with diabetes.
P2860
Q24628948-D264CF75-A496-4945-AC24-9B31A7321CBBQ26777177-FA3E562F-1012-4DC6-A574-C34DB553B03CQ28282265-2C1FB65F-E061-444F-9A8F-C3F52C0D1974Q30848457-8C10D7F8-5EA4-4392-8EB6-13FAA542D97BQ31155491-B32406D5-E97E-44C4-9067-B3C80E282AA0Q33428789-8F68624F-03FB-424C-B6C5-ABC6100A8CCDQ33562131-C9163EA5-B040-42F3-B8CA-3676451C7692Q33562235-369459BD-C406-4477-9C6D-1476B90DEC83Q33734024-A066F37E-D379-4CB1-8987-30FEBD159C4EQ33866808-988013FF-56E3-4EE1-9326-360EAEF3B82FQ34121402-AC9C7D87-7B38-4215-9E92-BB89CE2E9689Q34135837-9A1D54E9-BC1E-4A29-A918-AA8701047D9CQ34620430-A4015A08-A6A0-4C33-8C3B-11EB35A9B845Q34627077-9516B805-EF54-49D2-978C-0318313FA4A6Q36428062-95D65FB2-C815-4F64-B71B-D4BB3CA5E893Q36710078-605AA9C8-C737-4E34-8A54-E81FF9A8DBA3Q36710708-5F3E74C3-0B7C-4E76-A32F-C14668E1141DQ37378498-C77E398F-58D2-4296-B77A-240A3EFCBA27Q37609829-D0BE7699-AF75-453F-A50F-136AD8EF1A07Q37612696-333115F6-400D-44F0-9060-9CBBF732967BQ37624267-3BA5C0F3-2877-4652-BE2E-14D49D549E8DQ37638984-E6A33454-F1B1-4915-8E3D-D1E00190F3BCQ37721962-2A1A7528-1F2A-443A-804E-EF0D973CD5A0Q37857686-0E2ADE9F-2172-4E7F-B7C5-8C487DB57E55Q37869699-530FFA1D-7DF9-4D3C-A0CD-A2801DE2FD1AQ38020492-093F6178-7F5D-4433-9DAA-D077429B0C22Q38250719-6CD92EEF-5479-4996-962C-274CDCB5E2A6Q38410742-14DF8812-76F1-412E-8287-8AD6F58CEE7EQ38541323-C6772922-9318-46F1-BF77-7D64CC16C229Q38644070-4B3D2035-B5D7-405C-A0B5-80E478DB4FE7Q39136054-144EFCB0-C00C-4B71-AEA1-8C4EBA09260EQ39206561-42CB0CA1-BD8F-4E72-A7E5-436AA13C558AQ41900908-80606B3A-15FD-49D9-B4CB-E647F5DC9664Q41966262-547544E4-0EF0-472F-BB1A-CFBADBB8B3E4Q42171281-4540D5BD-B928-4EF7-A88A-0A727409DC03Q42585210-C8221114-4B6F-4629-83C4-90E7ADB1E243Q42933615-453D1602-795E-4413-B7B6-34C4041C2C7EQ50527571-CB97FF8E-C823-4642-8F09-622C89114FF0Q51759934-4397AF98-B7C3-4F93-8F98-E5E9E839AF07
P2860
Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Safety and tolerability of sit ...... 2 diabetes: a pooled analysis.
@en
Safety and tolerability of sit ...... 2 diabetes: a pooled analysis.
@nl
type
label
Safety and tolerability of sit ...... 2 diabetes: a pooled analysis.
@en
Safety and tolerability of sit ...... 2 diabetes: a pooled analysis.
@nl
prefLabel
Safety and tolerability of sit ...... 2 diabetes: a pooled analysis.
@en
Safety and tolerability of sit ...... 2 diabetes: a pooled analysis.
@nl
P2093
P2860
P356
P1476
Safety and tolerability of sit ...... 2 diabetes: a pooled analysis.
@en
P2093
Arlene S Swern
Bret Musser
Debora Williams-Herman
Elizabeth Round
John M Amatruda
Keith D Kaufman
Michael J Davies
Peter P Stein
P2860
P2888
P356
10.1186/1472-6823-8-14
P577
2008-10-27T00:00:00Z